Intrexon Announces Closing Of $230 Million Public Offering Of Common Stock Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
Published: Aug 26, 2015
GERMANTOWN, Md., Aug. 26, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today the closing of its previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 731,707 shares of common stock at the public offering price of $41.00 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by Intrexon to 5,609,756 shares and increased the total gross proceeds raised in the offering to approximately $230 million, before deducting the underwriting discounts, commissions, and estimated expenses.
JMP Securities LLC acted as sole book-running manager for the offering. Stifel acted as lead manager for the offering. Griffin Securities and Wunderlich Securities acted as co-managers for the offering.
The public offering was made pursuant to an automatic shelf registration statement on Form S-3ASR that was previously filed with the Securities and Exchange Commission (SEC). A final prospectus supplement relating to the offering has been filed with the SEC and is available on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement and accompanying base prospectus relating to the offering may also be obtained from JMP Securities LLC, 600 Montgomery Street, Suite 1100, San Francisco, California 94111 or by telephone: +1 (415) 835-8985.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA to create biologically-based products that improve the quality of life and the health of the planet. The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com.
Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Forward-Looking Safe Harbor Statement:
This press release contains certain forward-looking information about Intrexon Corporation, including statements about the company's public offering of securities and the intended use of proceeds therefrom, that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. All of such statements include certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the offering. Additional risks and uncertainties related to Intrexon's business include, but are not limited to: whether any of our other therapeutic discovery and development efforts will advance further in pre-clinical research or in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any other therapeutic products we develop will be successfully marketed if approved; our ability to achieve the results contemplated by our collaboration agreements; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; the development of, and our ability to take advantage of, the market for our therapeutic products; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Reports on Form 10-K for the fiscal year ended December 31, 2014 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2015. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
For more information about Intrexon Corporation, contact:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
Vice President, Investor Relations
Tel: +1 (561) 410-7052
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intrexon-announces-closing-of-230-million-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-300133473.html
SOURCE Intrexon Corporation